Isoxsuprine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag=
|authorTag={{SS}}
|genericName=Isoxsuprine
|aOrAn=a
|indication=cerebral vascular insufficiency, peripheral vascular disease of [[arteriosclerosis obliterans]], [[thromboangitis obliterans]] ([[Buerger's Disease]]) and [[Raynaud's disease]].
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|fdaLIADAdult=<h4>Cerebral Vascular Insufficiency</h4>


Gerald Chi
* Dosing information
:* '''10 to 20 mg PO tid or qid'''


<!--Overview-->
<h4>Peripheral Vascular Disease</h4>


|genericName=
* Dosing information
 
:* '''10 to 20 mg PO tid or qid'''
Isoxsuprine
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Isoxsuprine  in adult patients.
 
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Isoxsuprine  in adult patients.
|aOrAn=
|fdaLIADPed=FDA Package Insert for Isoxsuprine contains no information regarding FDA-labeled indications and dosage information for children.
 
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Isoxsuprine  in pediatric patients.
a
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Isoxsuprine  in pediatric patients.
 
|contraindications=There are no known contraindications to oral use when administered in recommended doses. Should not be given immediately postpartum or in the presence of arterial bleeding.
|drugClass=
|warnings=FDA Package Insert for Isoxsuprine contains no information regarding Warning.
 
|clinicalTrials=On rare occasions oral administration of the drug has been associated in time with the occurrences of [[hypotension]], [[tachycardia]], [[nausea]], [[vomiting]], [[dizziness]], abdominal distress, and severe [[rash]].  If rash appears the drug should be discontinued.
[[vasodilator]]
Although available evidence suggests a temporal association of these reactions with Isoxsuprine, a casual relationship can be neither confirmed nor refused.
 
|postmarketing=FDA Package Insert for Isoxsuprine contains no information regarding postmarketing experience.
|indication=
|drugInteractions=FDA Package Insert for Isoxsuprine contains no information regarding drug interactions.
 
|administration=Oral
cerebral [[vascular insufficiency]], [[arteriosclerosis obliterans]], [[thromboangitis obliterans]], and [[Raynaud's disease]]
|monitoring=FDA Package Insert for Isoxsuprine contains no information regarding drug monitoring.
 
|IVCompat=There is limited information about the IV Compatility.
|hasBlackBoxWarning=
|overdose=FDA Package Insert for Isoxsuprine contains no information regarding Adverse Reactions.
 
|drugBox={{chembox2
|adverseReactions=
| Verifiedfields = changed
 
| UNII_Ref = {{fdacite|correct|FDA}}
[[hypotension]], [[tachyarrhythmia]], [[rash]], [[abdominal discomfort]], [[nausea]], and [[dizziness]]
| UNII = R15UI3245N
 
| verifiedrevid = 444643797
<!--Black Box Warning-->
|ImageFile=Isoxsuprine.png
 
|ImageSize=150px
|blackBoxWarningTitle=
|IUPACName=4-{1-hydroxy-2-[(1-methyl-2-phenoxyethyl)amino]propyl}phenol
Title
|OtherNames=Vasodilian, Duvadilan
 
|Reference=<ref>[http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3783 Isoxsuprine - Compound Summary], [[PubChem]].</ref>
|blackBoxWarningBody=
|Section1={{Chembox Identifiers
<i><span style="color:#FF0000;">ConditionName: </span></i>
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
 
| ChemSpiderID = 3651
* Content
| InChI = 1/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3
 
| InChIKey = BMUKKTUHUDJSNZ-UHFFFAOYAW
<!--Adult Indications and Dosage-->
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
 
| StdInChI = 1S/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3
<!--FDA-Labeled Indications and Dosage (Adult)-->
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
 
| StdInChIKey = BMUKKTUHUDJSNZ-UHFFFAOYSA-N
|fdaLIADAdult=
| CASNo_Ref = {{cascite|correct|??}}
 
| CASNo=395-28-8
=====Cerebral Vascular Insufficiency, Arteriosclerosis Obliterans, Thromboangitis Obliterans, and Raynaud's Disease=====
| PubChem=3783
 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
* Dosing Information
| ChEMBL = 1197051
 
| KEGG_Ref = {{keggcite|correct|kegg}}
:* 10 to 20 mg three or four times daily
| KEGG = D08092
 
| SMILES = O(c1ccccc1)CC(NC(C)C(O)c2ccc(O)cc2)C
<!--Off-Label Use and Dosage (Adult)-->
| MeSHName=Isoxsuprine
 
| ATCCode_prefix = C04
<!--Guideline-Supported Use (Adult)-->
| ATCCode_suffix = AA01
 
  }}
|offLabelAdultGuideSupport=
|Section2={{Chembox Properties
 
| C = 18 | H=23|N=1|O=3
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| MolarMass=301.38012
 
|  Appearance=
<!--Non–Guideline-Supported Use (Adult)-->
|  Density=
 
|  MeltingPt=
|offLabelAdultNoGuideSupport=
|  BoilingPt=
 
| Solubility=
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
  }}
 
|Section3={{Chembox Hazards
<!--Pediatric Indications and Dosage-->
| MainHazards=
 
| FlashPt=
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|  Autoignition=
 
  }}
|fdaLIADPed=
}}
 
|mechAction=FDA Package Insert for Isoxsuprine contains no information regarding mechanism of action.
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
|structure=lsoxsuprine HCI occurs as a white odorless, crystalline powder, having a bitter
 
taste, It has a following structural formula
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
 
|contraindications=
 
* There are no known contraindications to oral use when administered in recommended doses.
 
<!--Warnings-->
 
|warnings=
 
* Should not be given immediately postpartum or in the presence of arterial [[bleeding]].
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
 
|clinicalTrials=
 
There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
<!--Postmarketing Experience-->
 
|postmarketing=
 
* On rare occasions oral administration of the drug has been associated in time with the occurrences of [[hypotension]], [[tachycardia]], [[nausea]], [[vomiting]], [[dizziness]], abdominal distress, and severe [[rash]].  If rash appears the drug should be discontinued.
* Although available evidence suggests a temporal association of these reactions with Isoxsuprine, a casual relationship can be neither confirmed nor refused.
 
<!--Drug Interactions-->
 
|drugInteractions=
 
There is limited information regarding <i>Drug Interactions</i> of {{PAGENAME}} in the drug label.
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=
 
There is no FDA guidance on the use of {{PAGENAME}} with respect to pregnant patients.
 
|useInPregnancyAUS=
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 
|useInNursing=
There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
 
|useInPed=
There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
 
|useInGeri=
There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
 
|administration=
 
* Oral
 
|monitoring=
 
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
<!--IV Compatibility-->
 
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
 
|overdose=
 
===Acute Overdose===
 
There is limited information regarding <i>Acute Overdose</i> of {{PAGENAME}} in the drug label.
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
 
|drugBox=
 
<!--Mechanism of Action-->
 
|mechAction=
 
<!--Structure-->
 
|structure=
 
* lsoxsuprine HCI occurs as a white odorless, crystalline powder, having a bitter taste, It has a following structural formula
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
 
|PD=
 
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
 
|PK=
 
There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
 
|nonClinToxic=
 
There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
 
|clinicalStudies=
 
There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
<!--How Supplied-->
 
|howSupplied=
 
* lsoxsuprine HCI 20mg tablets are supplied in HDPE containers of 1,000's.
 
<!--Patient Counseling Information-->
 
|fdaPatientInfo=
 
There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 
<!--Precautions with Alcohol-->
 
|alcohol=
 
* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
<!--Brand Names-->
 
|brandNames=
 
*  Vasodilan®<ref>{{Cite web | title = Isoxsuprine Hydrochloride (isoxsuprine hydrochloride) tablet | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e6582e24-9414-43b8-ac6f-b1422e3197cf }}</ref>
 
<!--Look-Alike Drug Names-->
 
|lookAlike=
 
* N/A<ref name="www.ismp.org">{{Cite web | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher = | date =  }}</ref>
 
<!--Drug Shortage Status-->


|drugShortage=
[[File:lsoxsuprine_structure_01.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]
|PD=FDA Package Insert for Isoxsuprine contains no information regarding pharmacodynamics.
|PK=FDA Package Insert for Isoxsuprine contains no information regarding pharmacokinetics.
|nonClinToxic=FDA Package Insert for Isoxsuprine contains no information regarding nonclinical toxicology.
|clinicalStudies=FDA Package Insert for Isoxsuprine contains no information regarding clinical studies.
|howSupplied=lsoxsuprine HCI 20mg tablets are supplied in HDPE containers of 1,000's
|alcohol=Alcohol-Isoxsuprine  interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
}}
}}
<!--Pill Image-->
{{PillImage
{{PillImage
|fileName=No image.jpg|This image is provided by the National Library of Medicine.
|fileName=No_image.jpg
|drugName=
|drugName=Isoxsuprine Hydrochloride 20 MG Oral Tablet
|NDC=
|NDC=61971-065
|drugAuthor=
|drugAuthor=Vista Pharmaceuticals, Inc
|ingredients=
|ingredients=lactose, cellulose, microcrystalline, calcium phosphate, dibasic, anhydrous, povidone k30, sodium starch glycolate type a potato, magnesium stearate
|pillImprint=
|pillImprint=20;VISTA065
|dosageValue=
|dosageValue=20
|dosageUnit=
|dosageUnit=mg
|pillColor=
|pillColor=White
|pillShape=
|pillShape=Round
|pillSize=
|pillSize=10.00
|pillScore=
|pillScore=2
}}
}}
<!--Label Display Image-->
{{LabelImage
{{LabelImage
|fileName={{PAGENAME}}02.png|This image is provided by the National Library of Medicine.
|fileName=Isoxsuprine_label_01.jpg
}}
}}
{{LabelImage
{{LabelImage
|fileName={{PAGENAME}}03.png|This image is provided by the National Library of Medicine.
|fileName=Isoxsuprine_panel_01.png
}}
}}
<!--Category-->
[[Category:Cardiovascular Drugs]]
[[Category:Drug]]
[[Category:Vasodilators]]

Revision as of 04:21, 27 July 2014

{{DrugProjectFormSinglePage |authorTag=Sheng Shi, M.D. [1] |genericName=Isoxsuprine |aOrAn=a |indication=cerebral vascular insufficiency, peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's Disease) and Raynaud's disease. |blackBoxWarningTitle=TITLE |blackBoxWarningBody=Condition Name: (Content)

|fdaLIADAdult=

Cerebral Vascular Insufficiency

  • Dosing information
  • 10 to 20 mg PO tid or qid

Peripheral Vascular Disease

  • Dosing information
  • 10 to 20 mg PO tid or qid

|offLabelAdultGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Isoxsuprine in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Isoxsuprine in adult patients. |fdaLIADPed=FDA Package Insert for Isoxsuprine contains no information regarding FDA-labeled indications and dosage information for children. |offLabelPedGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Isoxsuprine in pediatric patients. |offLabelPedNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Isoxsuprine in pediatric patients. |contraindications=There are no known contraindications to oral use when administered in recommended doses. Should not be given immediately postpartum or in the presence of arterial bleeding. |warnings=FDA Package Insert for Isoxsuprine contains no information regarding Warning. |clinicalTrials=On rare occasions oral administration of the drug has been associated in time with the occurrences of hypotension, tachycardia, nausea, vomiting, dizziness, abdominal distress, and severe rash. If rash appears the drug should be discontinued. Although available evidence suggests a temporal association of these reactions with Isoxsuprine, a casual relationship can be neither confirmed nor refused. |postmarketing=FDA Package Insert for Isoxsuprine contains no information regarding postmarketing experience. |drugInteractions=FDA Package Insert for Isoxsuprine contains no information regarding drug interactions. |administration=Oral |monitoring=FDA Package Insert for Isoxsuprine contains no information regarding drug monitoring. |IVCompat=There is limited information about the IV Compatility. |overdose=FDA Package Insert for Isoxsuprine contains no information regarding Adverse Reactions. |drugBox={{chembox2 | Verifiedfields = changed | UNII_Ref =  ☑Y | UNII = R15UI3245N | verifiedrevid = 444643797 |ImageFile=Isoxsuprine.png |ImageSize=150px |IUPACName=4-{1-hydroxy-2-[(1-methyl-2-phenoxyethyl)amino]propyl}phenol |OtherNames=Vasodilian, Duvadilan |Reference=[1] |Section1=! colspan=2 style="background: #f8eaba; text-align: center;" |Identifiers

|-

|

CAS Number

|

|-

|

3D model (JSmol)

|

|-



| ChEMBL

|

|- | ChemSpider

|

|-

| ECHA InfoCard | Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). |-

Template:Chembox E number


| KEGG

|

|- | MeSH | Isoxsuprine |-

|

PubChem CID

|

|-


| colspan="2" |

|-

| colspan="2" |

|- |Section2=! colspan=2 style="background: #f8eaba; text-align: center;" |Properties

|-

|

Chemical formula

| C18H23NO3

|- | Molar mass

| 301.38012

|- |Section3= }} |mechAction=FDA Package Insert for Isoxsuprine contains no information regarding mechanism of action. |structure=lsoxsuprine HCI occurs as a white odorless, crystalline powder, having a bitter taste, It has a following structural formula

This image is provided by the National Library of Medicine.

|PD=FDA Package Insert for Isoxsuprine contains no information regarding pharmacodynamics. |PK=FDA Package Insert for Isoxsuprine contains no information regarding pharmacokinetics. |nonClinToxic=FDA Package Insert for Isoxsuprine contains no information regarding nonclinical toxicology. |clinicalStudies=FDA Package Insert for Isoxsuprine contains no information regarding clinical studies. |howSupplied=lsoxsuprine HCI 20mg tablets are supplied in HDPE containers of 1,000's |alcohol=Alcohol-Isoxsuprine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. }} {{#subobject: 

 |Page Name=Isoxsuprine
 |Pill Name=No_image.jpg
 |Drug Name=Isoxsuprine Hydrochloride 20 MG Oral Tablet
 |Pill Ingred=lactose, cellulose, microcrystalline, calcium phosphate, dibasic, anhydrous, povidone k30, sodium starch glycolate type a potato, magnesium stearate|+sep=;
 |Pill Imprint=20;VISTA065
 |Pill Dosage=20 mg
 |Pill Color=White|+sep=;
 |Pill Shape=Round
 |Pill Size (mm)=10.00
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=Vista Pharmaceuticals, Inc
 |NDC=61971-065

}}

{{#subobject: 

 |Label Page=Isoxsuprine
 |Label Name=Isoxsuprine_label_01.jpg

}}

{{#subobject: 

 |Label Page=Isoxsuprine
 |Label Name=Isoxsuprine_panel_01.png

}}

  1. ↑ Isoxsuprine - Compound Summary, PubChem.
Retrieved from "https://www.wikidoc.org/index.php?title=Isoxsuprine&oldid=1002503"